造血干细胞移植治疗骨髓增生异常综合征的研究进展

 人类白细胞抗原（HLA）匹配同胞供者造血干细胞移植是治疗骨髓增生异常综合征（MDS）最有效的方法，其疗效在过去十几年里有明显的提高。在缺乏同胞供者来源时，无关供者移植、脐带血移植、自体造血干细胞移植可以作为替代的治疗选择。现对MDS患者移植适应证、影响移植疗效的因素（包括年龄、移植时机、移植前诱导缓解化疗、预处理方案、造血干细胞来源等）进行综述。

Advances of hematopoietic stem cell transplantation for patients with myelodysplastic syndromes

Hematopoietic cell transplantation (HSCT) offers the most effective therapy for patients with myclodysplastic syndromes (MDS) who have a human leukocyte antigen (HLA)-matched sibling donors and results have improved progressively over the past decade. For patients without an HLA-matched donor,volunteer unrelated donor(VUD) HSCT, unrelated cord blood allogeneic stem cell transplantation (CBT) and autologous HSCT may be the alternative. In this review the indication of transplantation and the prognostic factors for outcome after HSCT including patient age, timing of transplantation, induction chemotherapy before HSCT, conditioning regimens, source of stem cell were analysed.